Table 2.

Adverse events within the first 4 weeks after GD2-specific 4SCAR-T cell infusion

Adverse Event	No. of Patients (n = 8)			Adverse Event	No. of Patients (n = 8)
	Garde 2	Grade 3	Grade 4		Garde 2	Grade 3	Grade 4
Probably related				Respiratory
Central nervous system	0	0	0	Atelectasis	0	0	0
Headache	0	1	0	Pain
Seizure	1	0	0	Extremity	0	0	0
Unrelated				Bone	0	0	0
Hematologic toxic				Myalgia	4	1	0
Anemia	2	0	0	Musculoskeletal
Lymphopenia	4	1	0	Edema, localized	0	0	0
Neutropenia	5	0	0	Fracture	0	0	0
Thrombocytopenia	0	0	0	Central nervous system
Nonhematologic toxic				Headache	1	1	0
General				Seizure	0	0	0
Anorexia	0	0	0	Gait disturbance	0	0	0
Fatigue	1	0	0	Memory impairment	0	0	0
Somnolence	1	0	0	Tremors	0	0	0
Weakness	1	0	0	Cerebral edema	0	0	0
HEENT				Hydrocephalus	0	0	0
Eye paralysis, lateral	0	0	0	Infectious
Gastrointestinal				Urinary tract infection	0	0	0
Nausea	0	0	0	Laboratory test results
Diarrhea	0	0	0	Elevated ALT	0	0	0
Constipation	0	0	0	Elevated AST	0	0	0
Vomiting	0	0	0	Hyperbilirubinemia	0	0	0
Cardiac				Hyperkalemia	0	0	0
Bradycardia	0	0	0	Hypernatremia	0	0	0
				Hyponatremia	0	0	0